IGM Biosciences
  • Home
  • Overview
  • Technology
  • Pipeline
    • CD20 x CD3
    • Death Receptor 5
    • PD-L1 x ISA
    • OX40
    • GITR
  • Team
    • Fred M. Schwarzer
    • Bruce Keyt, PhD
    • Daniel S. Chen, MD, PhD
    • Misbah Tahir
    • Ramesh Baliga, PhD
    • Stephen F. Carroll, PhD
    • Wayne Godfrey, MD
    • Marvin S. Peterson, PhD
    • Angus M. Sinclair, PhD
  • News & Publications
  • Join Us
  • Contact Us
  • Menu

Category Archives: publications

Multimeric Anti-DR5 IgM antibody displays potent cytotoxicity in vitro and promotes tumor regression in vivo

Posted on April 25, 2017August 2, 2018 by IGM

Continue reading→

High Avidity Anti-CD20 IgM Antibody for Enhanced Complement-Dependent Cell Killing of Low CD20 Expressing Tumor Cells

Posted on April 25, 2016August 2, 2018 by IGM

Continue reading→

IGM-55.5, a novel monoclonal human recombinant IgM antibody with potent activity against B cell leukemia and lymphoma

Posted on April 25, 2014August 2, 2018 by IGM

Continue reading→

  • Home
  • Overview
  • Technology
  • Pipeline
    • CD20 x CD3
    • Death Receptor 5
    • PD-L1 x ISA
    • OX40
    • GITR
  • Team
    • Fred M. Schwarzer
    • Bruce Keyt, PhD
    • Daniel S. Chen, MD, PhD
    • Misbah Tahir
    • Ramesh Baliga, PhD
    • Stephen F. Carroll, PhD
    • Wayne Godfrey, MD
    • Marvin S. Peterson, PhD
    • Angus M. Sinclair, PhD
  • News & Publications
  • Join Us
  • Contact Us
All content © IGM Biosciences, Inc.
A SiteOrigin Theme